Association of an UCP4 (SLC25A27) haplotype with ultra-resistant schizophrenia

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Saha S, Chant D, Welham J, Mcgrath J: A systematic review of the prevalence of schizophrenia. PLoS Med.2(5),e141 (2005).
  MedlineGoogle Scholar
• 2  Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet349(9063),1436–1442 (1997).
  Medline CASGoogle Scholar
• 3  Lewis DA, Levitt P: Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci.25,409–432 (2002).
  Medline CASGoogle Scholar
• 4  Marenco S, Weinberger DR: The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev. Psychopathol.12(3),501–527 (2000).
  Medline CASGoogle Scholar
• 5  Rapoport JL, Addington AM, Frangou S, Psych MR: The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry10(5),434–449 (2005).
  Medline CASGoogle Scholar
• 6  Weinberger DR, Mcclure RK: Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch. Gen. Psychiatry59(6),553–558 (2002).
  MedlineGoogle Scholar
• 7  Mccullumsmith RE, Clinton SM, Meador-Woodruff JH: Schizophrenia as a disorder of neuroplasticity. Int. Rev. Neurobiol.59,19–45 (2004).
  Medline CASGoogle Scholar
• 8  Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biol. Psychiatry50(11),898–911 (2001).
  Medline CASGoogle Scholar
• 9  Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry45(9),789–796 (1988).
  Medline CASGoogle Scholar
• 10  Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry158(4),518–526 (2001).
  Medline CASGoogle Scholar
• 11  Rosenheck R, Cramer J, Xu W et al.: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of veterans affairs cooperative study group on clozapine in refractory schizophrenia. N. Engl. J. Med.337(12),809–815 (1997).
  Medline CASGoogle Scholar
• 12  Wahlbeck K, Cheine M, Essali A, Adams C: Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am. J. Psychiatry156(7),990–999 (1999).
  Medline CASGoogle Scholar
• 13  Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J: When symptoms persist: clozapine augmentation strategies. Schizophr. Bull.27(4),615–628 (2001).
  Medline CASGoogle Scholar
• 14  Elkis H: Treatment-resistant schizophrenia. Psychiatr. Clin. North Am.30(3),511–533 (2007).
  MedlineGoogle Scholar
• 15  Mouaffak F, Tranulis C, Gourevitch R et al.: Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin. Neuropharmacol.29(1),28–33 (2006).▪ Proposes an operational definition of schizophrenia refractory to clozapine (‘ultra-resistant schizophrenia’) for the implementation and homogenization of future therapeutic trials.
  Medline CASGoogle Scholar
• 16  Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry10(1),40–68, image 45 (2005).
  Medline CASGoogle Scholar
• 17  Macdonald ML, Eaton ME, Dudman JT, Konradi C: Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol. Psychiatry57(9),1041–1051 (2005).
  Medline CASGoogle Scholar
• 18  Matsumoto M, Shikanai H, Togashi H et al.: Characterization of clozapine-induced changes in synaptic plasticity in the hippocampal-MPCF pathway of anesthetized rats. Brain Res.1195,50–55 (2008).
  Medline CASGoogle Scholar
• 19  Arranz MJ, De Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry12(8),707–747 (2007).▪▪ Summarizes the key findings from the last decade of research in pharmcogenetics and pharmacogenomics of schizophrenia.
  Medline CASGoogle Scholar
• 20  Hagberg H: Mitochondrial impairment in the developing brain after hypoxia-ischemia. J. Bioenerg. Biomembr.36(4),369–373 (2004).
  Medline CASGoogle Scholar
• 21  Krebs MO, Bellon A, Mainguy G, Jay TM, Frieling H: One-carbon metabolism and schizophrenia: current challenges and future directions. Trends Mol. Med.15(12),562–570 (2009).▪ Discusses the potential roles of one-carbon metabolism in the pathophysiology of schizophrenia.
  Medline CASGoogle Scholar
• 22  Prabakaran S, Swatton JE, Ryan MM et al.: Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry9(7),684–697, 643 (2004).▪ Proposes that oxidative stress and the ensuing cellular adaptations are linked to the schizophrenia disease process.
  Medline CASGoogle Scholar
• 23  Uranova NA, Orlovskaia DD, Vikhreva OV, Zimina IS, Rakhmanova VI: [Morphometric study of ultrastructural changes in oligodendroglial cells in the postmortem brain in endogenous psychoses]. Vestn. Ross. Akad. Med Nauk (7),42–48 (2001).
  MedlineGoogle Scholar
• 24  Kung L, Roberts RC: Mitochondrial pathology in human schizophrenic striatum: a postmortem ultrastructural study. Synapse31(1),67–75 (1999).
  Medline CASGoogle Scholar
• 25  Kolomeets NS: [The role of microglia reactivity in the cerebral pathology in schizophrenia]. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova109(3),60–63 (2009).
  Medline CASGoogle Scholar
• 26  Regenold WT, Phatak P, Marano CM, Sassan A, Conley RR, Kling MA: Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol. Psychiatry65(6),489–494 (2009).
  Medline CASGoogle Scholar
• 27  Kroemer G, Reed JC: Mitochondrial control of cell death. Nat. Med.6(5),513–519 (2000).
  Medline CASGoogle Scholar
• 28  Nicholls DG, Ward MW: Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci.23(4),166–174 (2000).
  Medline CASGoogle Scholar
• 29  Andrews ZB, Diano S, Horvath TL: Mitochondrial uncoupling proteins in the CNS: in support of function and survival. Nat. Rev. Neurosci.6(11),829–840 (2005).▪▪ Presents data on the regulation and function of neuronal uncoupling proteins.
  Medline CASGoogle Scholar
• 30  Mao W, Yu XX, Zhong A et al.: UCP4, a novel brain-specific mitochondrial protein that reduces membrane potential in mammalian cells. FEBS Lett.443(3),326–330 (1999).
  Medline CASGoogle Scholar
• 31  Sanchis D, Fleury C, Chomiki N et al.: Bmcp1, a novel mitochondrial carrier with high expression in the central nervous system of humans and rodents, and respiration uncoupling activity in recombinant yeast. J. Biol. Chem.273(51),34611–34615 (1998).
  Medline CASGoogle Scholar
• 32  Fleury C, Neverova M, Collins S et al.: Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat. Genet.15(3),269–272 (1997).
  Medline CASGoogle Scholar
• 33  Diano S, Matthews RT, Patrylo P et al.: Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology144(11),5014–5021 (2003).
  Medline CASGoogle Scholar
• 34  Chu AC, Ho PW, Kwok KH et al.: Mitochondrial UCP4 attenuates MPP+ - and dopamine-induced oxidative stress, mitochondrial depolarization, and ATP deficiency in neurons and is interlinked with ucp2 expression. Free Radic. Biol. Med.46(6),810–820 (2009).
  Medline CASGoogle Scholar
• 35  Ho PW, Chu AC, Kwok KH, Kung MH, Ramsden DB, Ho SL: Knockdown of uncoupling protein-5 in neuronal SH-SY5Y cells: Effects on MPP+-induced mitochondrial membrane depolarization, ATP deficiency, and oxidative cytotoxicity. J. Neurosci. Res.84(6),1358–1366 (2006).
  Medline CASGoogle Scholar
• 36  Chan SL, Liu D, Kyriazis GA, Bagsiyao P, Ouyang X, Mattson MP: Mitochondrial uncoupling protein-4 regulates calcium homeostasis and sensitivity to store depletion-induced apoptosis in neural cells. J. Biol. Chem.281(49),37391–37403 (2006).
  Medline CASGoogle Scholar
• 37  Trenker M, Malli R, Fertschai I, Levak-Frank S, Graier WF: Uncoupling proteins 2 and 3 are fundamental for mitochondrial ca2⁺ uniport. Nat. Cell Biol.9(4),445–452 (2007).
  Medline CASGoogle Scholar
• 38  Ben-Shachar D, Laifenfeld D: Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol.59,273–296 (2004).▪▪ Proposes that mitochondrial dysfunction in schizophrenia could cause, or arise from, anomalies in processes of plasticity.
  Medline CASGoogle Scholar
• 39  Ng F, Berk M, Dean O, Bush AI: Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol.11(6),851–876 (2008).▪ Proposes that oxidative mechanisms may form unifying common pathogenic pathways in psychiatric disorders.
  Medline CASGoogle Scholar
• 40  Yu WY, Chang HW, Lin CH, Cho CL: Short telomeres in patients with chronic schizophrenia who show a poor response to treatment. J. Psychiatry Neurosci.33(3),244–247 (2008).▪ Oxidative stress, whose marker is shortened telomere, and the ensuing cellular dysfunction may be a factor contributing to the deterioration in treatment-resistant schizophrenia.
  MedlineGoogle Scholar
• 41  Nishioka N, Arnold SE: Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am. J. Geriatr. Psychiatry12(2),167–175 (2004).
  MedlineGoogle Scholar
• 42  Yasuno K, Ando S, Misumi S et al.: Synergistic association of mitochondrial uncoupling protein (UCP) genes with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet.144B(2),250–253 (2007).▪ First report of an association between schizophrenia and neuronal uncoupling proteins.
  MedlineGoogle Scholar
• 43  Nurnberger JI Jr, Blehar MC, Kaufmann CA et al.: Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH genetics initiative. Arch. Gen. Psychiatry51(11),849–859; discussion 863–844 (1994).
  MedlineGoogle Scholar
• 44  American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, DSM-IV, (4th Edition). American Psychiatric Association, Washington, DC, USA (1994).
  Google Scholar
• 45  Ventura J, Lukoff D, Nuechterlein KH, Liberman RP, Green MFS, Shaner A: Manual for the expanded Brief Psychiatic Rating Scale. Int. J. Methods Psych. Res.3,227–244 (1993).
  Google Scholar
• 46  Ventura J, Green MF, Shaner A, Lieberman RP: Training and quality assurance with the Brief Psychiatic Rating Scale: the drift busters. Int. J. Methods Psychiatr. Res.3,221–244 (1993).
  Google Scholar
• 47  Mouaffak F, Morvan Y, Bannour S et al.: Validation of the French version of the expanded Brief Psychiatic Rating Scale with anchor BPRS-E(A). Encephale36(4),294–301 (2009).
  MedlineGoogle Scholar
• 48  Guy W (Ed.): Clinical Global Impressions. In: Ecdeu Assessment Manual for Psychopharmacology, Revised Department of Health, Education and Welfare, MD, USA, 218–222 (1976).
  Google Scholar
• 49  Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull.13(2),261–276 (1987).
  Medline CASGoogle Scholar
• 50  Overall JE, Gorham DR: The Brief Psychiatic Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol. Bull.24,97–99 (1988).
  Google Scholar
• 51  Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics21(2),263–265 (2005).
  Medline CASGoogle Scholar
• 52  Gabriel SB, Schaffner SF, Nguyen H et al.: The structure of haplotype blocks in the human genome. Science296(5576),2225–2229 (2002).
  Medline CASGoogle Scholar
• 53  Cipriani A, Boso M, Barbui C: Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst. Rev. (3),CD006324 (2009).
  MedlineGoogle Scholar
• 54  Barbui C, Signoretti A, Mule S, Boso M, Cipriani A: Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr. Bull.35(2),458–468 (2009).
  MedlineGoogle Scholar
• 55  Taylor DM, Smith L: Augmentation of clozapine with a second antipsychotic – a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr. Scand.119(6),419–425 (2009).
  Medline CASGoogle Scholar
• 56  Szolnoki Z, Kondacs A, Mandi Y, Bodor A, Somogyvari F: A homozygous genetic variant of mitochondrial uncoupling protein 4 exerts protection against the occurrence of multiple sclerosis. Neuromolecular Med.11(2),101–105 (2009).
  Medline CASGoogle Scholar
• 57  Feinstein A, Du Boulay G, Ron MA: Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Br. J. Psychiatry161,680–685 (1992).
  Medline CASGoogle Scholar
• 58  Smorodchenko A, Rupprecht A, Sarilova I et al.: Comparative analysis of uncoupling protein 4 distribution in various tissues under physiological conditions and during development. Biochim. Biophys. Acta1788(10),2309–2319 (2009).▪ Provides data on the developmental expression pattern of UCP4.
  Medline CASGoogle Scholar
• 59  Mattson MP: Brain evolution and lifespan regulation: Conservation of signal transduction pathways that regulate energy metabolism. Mech. Ageing Dev.123(8),947–953 (2002).
  Medline CASGoogle Scholar
• 60  Mattson MP, Liu D: Mitochondrial potassium channels and uncoupling proteins in synaptic plasticity and neuronal cell death. Biochem. Biophys. Res. Commun.304(3),539–549 (2003).
  Medline CASGoogle Scholar
• 61  Sahin E, Depinho RA: Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature464(7288),520–528 (2010).
  Medline CASGoogle Scholar
• 62  Passos JF, Saretzki G, Ahmed S et al.: Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol.5(5),e110 (2007).
  MedlineGoogle Scholar
• 63  Kao HT, Cawthon RM, Delisi LE et al.: Rapid telomere erosion in schizophrenia. Mol. Psychiatry13(2),118–119 (2008).
  Medline CASGoogle Scholar
• 64  Ericson E, Gebbia M, Heisler LE et al.: Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. PLoS Genet.4(8),e1000151 (2008).▪▪ Proposes that mitochondrial reactive oxygen species is a major determinant of telomere-dependent senescence.
  MedlineGoogle Scholar